Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and human...

Descripción completa

Detalles Bibliográficos
Autores principales: Cross, Robert W., Bornholdt, Zachary A., Prasad, Abhishek N., Geisbert, Joan B., Borisevich, Viktoriya, Agans, Krystle N., Deer, Daniel J., Melody, Kevin, Fenton, Karla A., Feldmann, Heinz, Sprecher, Armand, Zeitlin, Larry, Geisbert, Thomas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385100/
https://www.ncbi.nlm.nih.gov/pubmed/32719371
http://dx.doi.org/10.1038/s41467-020-17446-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385100/
https://www.ncbi.nlm.nih.gov/pubmed/32719371
http://dx.doi.org/10.1038/s41467-020-17446-4

Ejemplares similares